On September 14, HANSOH PHARMA rose 3.12% in regular trading, trading at HK$33.72/share, with turnover of HK$69.13 million. The rally was driven by landmark clinical data presented at the World Lung Cancer Conference.

On September 13, HANSOH PHARMA's proprietary B7-H3-targeted ADC, risvutatug rezetecan, was presented as a late-breaking oral abstract at the conference's presidential symposium. The interim analysis of the Phase III ARTEMIS-008 study showed median overall survival of 18.5 months in the risvutatug rezetecan arm versus 10.3 months for topotecan, representing a 54% reduction in the risk of death. This sets a new global record for the longest OS in second-line small cell lung cancer treatment and marks the first-ever randomized Phase III trial to confirm an OS benefit from a B7-H3-targeted ADC.

The data builds on a series of recent regulatory milestones. On September 11, the drug was granted priority review status by China's NMPA based on ARTEMIS-008 results, following acceptance of its biologics license application on September 2. The company previously reported strong H1 results on August 26, with revenue of RMB 8.3 billion and attributable profit up 35.8% year-over-year to RMB 4.26 billion, with innovative drug revenue accounting for a record 85.4% of total sales.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)